OC
BIOL

Oppenheimer & Co’s Biolase, Inc. BIOL Stock Holding History

Oppenheimer & Co’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2
Closed -$57K – 1481
2013
Q4 		$57K Buy
+2
New +$47.4K ﹤0.01% 1342

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return

Oppenheimer & Co's BIOL Position: Q1 2014 in Review

Oppenheimer & Co sold out of Biolase, Inc. (BIOL) in Q1 2014, closing a stake of 2 shares — an estimated $57K sold.

Oppenheimer & Co first reported a position in BIOL in Q4 2013 and held it in 1 quarter. The position peaked at $57K in Q4 2013. 44 funds tracked by Wall St. Rank hold BIOL as of Q1 2014.

  • Oppenheimer & Co reported no remaining Biolase, Inc. position as of Q1 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 2 Biolase, Inc. shares in Q1 2014, an estimated $57K.
  • Oppenheimer & Co first reported a position in Biolase, Inc. in Q4 2013 and held it in 1 quarter.
  • Oppenheimer & Co's Biolase, Inc. position peaked at $57K in Q4 2013.
  • 44 funds tracked by Wall St. Rank held Biolase, Inc. as of Q1 2014.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.